IL6 and COVID-19: Intriguingly, severe COVID-19 patients display massive inflammation, possibly resulting from the loss of homeostatic robustness, which is clinically mitigated by the treatment with monoclonal antibodies against IL-6 (e.g., tocilizumab) (4) and/or corticosteroids (5).